Across TCGA pan-cancer cohorts, IGHD3-16 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of IGHD3-16’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where IGHD3-16 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IGHD3-16 is over-expressed in tumor, although a few such as COAD and STAD show the opposite, repressed pattern.

LUAD, KIRC, and COAD are the cancer types where IGHD3-16 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGHD3-16 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	All	+1.145	<.001	7	view →
KIRC	All	All	+0.311	.001	6	view →
COAD	All	IV	−1.444	.004	5	view →
STAD	Male	IV	−3.190	.015	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: IGHD3-16 RNA expression & survival · all IGHD3-16 data types